BBA
RLMD icon

Baker Bros. Advisors’s Relmada Therapeutics RLMD Stock Holding History

Baker Bros. Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-495,113
Closed -$18.3M – 119
2022
Q3 		$18.3M Hold
495,113
– – 0.12% 50
2022
Q2 		$9.4M Hold
495,113
– – 0.05% 61
2022
Q1 		$13.4M Hold
495,113
– – 0.08% 58
2021
Q4 		$11.2M Buy
495,113
+294,117
+146% +$6.54M 0.05% 73
2021
Q3 		$5.27M Buy
200,996
+124,396
+162% +$3.33M 0.02% 93
2021
Q2 		$2.45M Buy
+76,600
New +$2.66M 0.01% 109

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baker Bros. Advisors's RLMD Position: Q4 2022 in Review

Baker Bros. Advisors sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 495,113 shares — an estimated $18.3M sold.

Baker Bros. Advisors first reported a position in RLMD in Q2 2021 and held it in 6 quarters. The position peaked at $18.3M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Baker Bros. Advisors reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 495,113 Relmada Therapeutics shares in Q4 2022, an estimated $18.3M.
  • Baker Bros. Advisors first reported a position in Relmada Therapeutics in Q2 2021 and held it in 6 quarters.
  • Baker Bros. Advisors's Relmada Therapeutics position peaked at $18.3M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.